Schrodinger Inc. (SDGR) News
Filter SDGR News Items
SDGR News Results
|Loading, please wait...|
SDGR News Highlights
- SDGR's 30 day story count now stands at 4.
- Over the past 26 days, the trend for SDGR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG and VIEW are the most mentioned tickers in articles about SDGR.
Latest SDGR News From Around the Web
Below are the latest news stories about SCHRODINGER INC that investors may wish to consider to help them evaluate SDGR as an investment opportunity.
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.
NEW YORK, November 17, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 13, 2023, the company granted (i) non-statutory stock options to purchase 14,400 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 10,050 shares of the company’s common stock to 13 newly hired employees. These grants were m
Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks.
We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare.
NEW YORK, November 06, 2023--Schrödinger today announced that management will participate in two conferences in November.
With recent data indicating AI is saving companies loads of money, three AI stocks to buy are exploiting this trend.
Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript November 1, 2023 Schrödinger, Inc. misses on earnings expectations. Reported EPS is $-0.86 EPS, expectations were $-0.69. Operator: Welcome to Schrödinger’s Conference Call to review Third Quarter 2023 Financial Results. My name is Eric and I will be your operator for today’s call. All lines have been […]
Q3 2023 Schrodinger Inc Earnings Call
Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
NEW YORK, November 02, 2023--Schrödinger today announced that new data on SGR-1505, its MALT1 inhibitor, and SGR-2921, its CDC7 inhibitor, will be presented at ASH.
With the frothiness of the artificial intelligence (AI) craze in full swing, Schrödinger (NASDAQ: SDGR) is a biotech that investors should know about now. While many questions remain about the viability of its business model and its ability to grow in the long term in the face of mounting competition, for the moment it's one of the leaders in the field of information technology-driven drug development. Schrödinger is a leader in the field of technology-assisted drug discovery and development.